Navigation Links
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
Date:7/7/2011

AMSTERDAM, July 7, 2011 /PRNewswire/ --


Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has filed a request for re-examination of the Marketing Authorisation Application for Glybera® with the European Medicines Agency. Glybera is a gene therapy for the genetic disorder lipoprotein lipase deficiency. The Company expects that the re-examination of the dossier will be completed by the end of 2011.

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "st
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
2. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
5. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. Elsevier and Molecular Connections Develop Two New Applications on SciVerse Applications
10. Biochemist and Geneticist Ronald W. Davis Receives $500,000 Gruber Genetics Prize for Pioneering Work in the Development of Biotechnologies that Have Significantly Advanced the Fields of Molecular Genetics and Genomics
11. NIH grant ratchets up ASU research in molecular motors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... 07, 2015 , ... CSM, a leading clinical trial supply company, today announced ... has an extensive background in financial management and accounting, bringing over 20 years of ... role, Morse will oversee all financial areas of the company to both strengthen CSM’s ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia ... to innovation in life science R&D, has attracted a number of new members ... top ten pharmaceutical company joining as a Core member, and DNAnexus and Tessella ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt through genetic ... spread, and how that battle leaves them temporarily weakened. These insights may provide ...
(Date:7/6/2015)...  Approximately 1% of the population inherits a common ... individuals are three times more likely to develop angina, ... the nation,s leading medical journals by researchers from the ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 The ... (also known as "sixth disease") and occasional seizures in ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Pistoia Alliance Continues to Attract New Members 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... GENEVA , February 3 Viroblock SA, ... products, today,announced that Dr. Jamie Paterson will join Viroblock ... Paterson , a British national, can look back at 20 years ... Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter & ...
... This release is available in German . ... A white light appears out of nowhere. And a light ... upon close examination does the source of the apparently supernatural ... passes through thousands of infinitesimal lens structures measuring only a ...
... ... drug development community thanks to their complexity and substantial potential benefits for sponsors and patients. ... Inc. discusses the rapid evolution of the adaptive trial model and the latest thinking about ... ...
Cached Biology Technology:Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2Nano for the senses 2Nano for the senses 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 2Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 3Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies 4
(Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
(Date:6/17/2015)... PALM BEACH GARDENS, Fla. , June 17, ... identity management solutions, today announced that its U.are.U ... by Togo,s Eateries, Inc., ... based fast casual sandwich chain, to increase security, ... (POS). The Crossmatch fingerprint readers enable instant, non-repudiable identity ...
(Date:6/16/2015)... YORK , June 16, 2015  With the ... world, security remains a top concern. The recent compromise ... confirms the need for strong authentication within government agencies. ... Token, a biometric one-time password (OTP) authenticator, has been ... Standards (FIPS) 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... Jewish Health and four other research centers have been ... Heart Lung and Blood Institute as part of the ... national scientists to delve deeply into the biology of ... therapeutic options. The multi-center Lung Genomics Research Consortium will ...
... CITY, Calif., Oct. 7 DigitalPersona, Inc., a ... announced that Panasonic System Solutions Company is now ... field-upgradeable option on Panasonic,s modular point-of-sale (POS) workstation, ... a modular case that can be attached to ...
... degradation in dryland regions continuing to worsen, the ... scientist-recommended indicators for monitoring and assessing desertification that ... agreement was reached after two weeks of negotiations ... the Ninth Session of the Conference of the ...
Cached Biology News:NHLBI awards $11 million for molecular roadmap to chronic lung diseases 2Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
Request Info...
... new Thermo Electron RapidStak provides valuable walk-away ... a unique buffer nest technology for parallel ... RapidStak provides fast, reliable automation for any ... walk-away confidence. The RapidStak can be set-up ...
... genetically engineered endonuclease. This unique enzyme degrades ... having no proteolytic activity. It is effective ... possesses an exceptionally high specific activity. Ideal ... proteins, its use enables compliance with FDA ...
Biology Products: